Advanced Biomed Inc. Completes 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance

summarizeSummary

Advanced Biomed Inc. has completed its 1-for-20 reverse stock split, effective February 20, 2026, as a measure to regain compliance with Nasdaq's minimum bid price requirement.

check_boxKey Events

• Reverse Stock Split Effective

  The company's 1-for-20 reverse stock split became effective on February 20, 2026, with shares beginning to trade on a post-split basis on The Nasdaq Capital Market.

• Nasdaq Compliance Objective

  The split was implemented to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, following a delisting notice received on January 21, 2026.

• Share Structure Adjustment

  Every twenty (20) shares of common stock were automatically converted into one (1) share, reducing the total issued and outstanding common shares from approximately 27.29 million to 1.36 million. Authorized shares and par value remain unchanged.

• Follows Prior Disclosures

  This action follows the shareholder approval confirmed in the DEF 14C filing on January 23, 2026, and the board's approval of the 1-for-20 ratio on January 30, 2026.

auto_awesomeAnalysis

This 8-K confirms the execution of the previously approved 1-for-20 reverse stock split, a critical step for Advanced Biomed Inc. to maintain its Nasdaq listing following a delisting notice. While necessary for compliance, reverse stock splits often signal underlying financial distress and can lead to further stock price volatility. Investors should monitor whether the company successfully maintains its bid price and addresses its ongoing going concern warning and highly dilutive financing activities.